These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 26358191

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides.
    Windisch M, Hutter-Paier B, Rockenstein E, Hashimoto M, Mallory M, Masliah E.
    J Mol Neurosci; 2002; 19(1-2):63-9. PubMed ID: 12212795
    [Abstract] [Full Text] [Related]

  • 23. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.
    Recasens A, Dehay B, Bové J, Carballo-Carbajal I, Dovero S, Pérez-Villalba A, Fernagut PO, Blesa J, Parent A, Perier C, Fariñas I, Obeso JA, Bezard E, Vila M.
    Ann Neurol; 2014 Mar; 75(3):351-62. PubMed ID: 24243558
    [Abstract] [Full Text] [Related]

  • 24. Proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice.
    Tanji K, Mori F, Mimura J, Itoh K, Kakita A, Takahashi H, Wakabayashi K.
    Acta Neuropathol; 2010 Aug; 120(2):145-54. PubMed ID: 20339856
    [Abstract] [Full Text] [Related]

  • 25. Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation.
    Pal GD, Ouyang B, Serrano G, Shill HA, Goetz C, Stebbins G, Metman LV, Driver-Dunckley E, Mehta SH, Caviness JN, Sabbagh MN, Adler CH, Beach TG, Arizona Study of Aging Neurodegenerative Disorders.
    Mov Disord; 2017 Feb; 32(2):274-277. PubMed ID: 27911008
    [Abstract] [Full Text] [Related]

  • 26. α-Synuclein in the olfactory system in Parkinson's disease: role of neural connections on spreading pathology.
    Ubeda-Bañon I, Saiz-Sanchez D, de la Rosa-Prieto C, Martinez-Marcos A.
    Brain Struct Funct; 2014 Sep; 219(5):1513-26. PubMed ID: 24135772
    [Abstract] [Full Text] [Related]

  • 27. Direct α-synuclein promoter transactivation by the tumor suppressor p53.
    Duplan E, Giordano C, Checler F, Alves da Costa C.
    Mol Neurodegener; 2016 Feb 02; 11():13. PubMed ID: 26833254
    [Abstract] [Full Text] [Related]

  • 28. Lewy Body Disease Primate Model with α-Synuclein Propagation from the Olfactory Bulb.
    Sawamura M, Onoe H, Tsukada H, Isa K, Yamakado H, Okuda S, Ikuno M, Hatanaka Y, Murayama S, Uemura N, Isa T, Takahashi R.
    Mov Disord; 2022 Oct 02; 37(10):2033-2044. PubMed ID: 35989519
    [Abstract] [Full Text] [Related]

  • 29. Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term.
    Rey NL, George S, Steiner JA, Madaj Z, Luk KC, Trojanowski JQ, Lee VM, Brundin P.
    Acta Neuropathol; 2018 Jan 02; 135(1):65-83. PubMed ID: 29209768
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.
    Welander H, Bontha SV, Näsström T, Karlsson M, Nikolajeff F, Danzer K, Kostka M, Kalimo H, Lannfelt L, Ingelsson M, Bergström J.
    Biochem Biophys Res Commun; 2011 Aug 19; 412(1):32-8. PubMed ID: 21798243
    [Abstract] [Full Text] [Related]

  • 32. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders.
    Beach TG, White CL, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, Sue LI, Sasse J, Bachalakuri J, Henry-Watson J, Akiyama H, Adler CH, Arizona Parkinson's Disease Consortium.
    Acta Neuropathol; 2009 Feb 19; 117(2):169-74. PubMed ID: 18982334
    [Abstract] [Full Text] [Related]

  • 33. Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients.
    Recasens A, Carballo-Carbajal I, Parent A, Bové J, Gelpi E, Tolosa E, Vila M.
    Acta Neuropathol Commun; 2018 Feb 08; 6(1):8. PubMed ID: 29422109
    [Abstract] [Full Text] [Related]

  • 34. Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain-derived α-synuclein.
    Limegrover CS, Yurko R, Izzo NJ, LaBarbera KM, Rehak C, Look G, Rishton G, Safferstein H, Catalano SM.
    J Neurosci Res; 2021 Apr 08; 99(4):1161-1176. PubMed ID: 33480104
    [Abstract] [Full Text] [Related]

  • 35. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
    Jellinger KA.
    Acta Neuropathol; 2003 Sep 08; 106(3):191-201. PubMed ID: 12845452
    [Abstract] [Full Text] [Related]

  • 36. Regulatory Mechanism of miR-543-3p on GLT-1 in a Mouse Model of Parkinson's Disease.
    Wu X, Meng X, Tan F, Jiao Z, Zhang X, Tong H, He X, Luo X, Xu P, Qu S.
    ACS Chem Neurosci; 2019 Mar 20; 10(3):1791-1800. PubMed ID: 30676715
    [Abstract] [Full Text] [Related]

  • 37. The effect of mutant GBA1 on accumulation and aggregation of α-synuclein.
    Maor G, Rapaport D, Horowitz M.
    Hum Mol Genet; 2019 Jun 01; 28(11):1768-1781. PubMed ID: 30615125
    [Abstract] [Full Text] [Related]

  • 38. Alpha-synuclein pathology in the olfactory pathways of dementia patients.
    Hubbard PS, Esiri MM, Reading M, McShane R, Nagy Z.
    J Anat; 2007 Jul 01; 211(1):117-24. PubMed ID: 17553102
    [Abstract] [Full Text] [Related]

  • 39. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein.
    Marxreiter F, Nuber S, Kandasamy M, Klucken J, Aigner R, Burgmayer R, Couillard-Despres S, Riess O, Winkler J, Winner B.
    Eur J Neurosci; 2009 Mar 01; 29(5):879-90. PubMed ID: 19291219
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.